DaVita Inc. (NYSE:DVA) Shares Sold by LSV Asset Management

LSV Asset Management reduced its position in shares of DaVita Inc. (NYSE:DVA - Free Report) by 2.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,028,429 shares of the company's stock after selling 25,400 shares during the quarter. LSV Asset Management owned about 1.25% of DaVita worth $153,802,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of DVA. Captrust Financial Advisors increased its holdings in shares of DaVita by 16.6% in the 3rd quarter. Captrust Financial Advisors now owns 3,992 shares of the company's stock valued at $654,000 after acquiring an additional 569 shares during the period. Benjamin Edwards Inc. purchased a new position in DaVita during the 3rd quarter worth $207,000. HighTower Advisors LLC increased its position in DaVita by 11.3% during the 3rd quarter. HighTower Advisors LLC now owns 23,335 shares of the company's stock valued at $3,813,000 after buying an additional 2,376 shares in the last quarter. Janus Henderson Group PLC raised its stake in DaVita by 8.5% in the third quarter. Janus Henderson Group PLC now owns 5,847 shares of the company's stock valued at $958,000 after buying an additional 457 shares during the last quarter. Finally, National Bank of Canada FI boosted its holdings in DaVita by 14.6% in the third quarter. National Bank of Canada FI now owns 38,232 shares of the company's stock worth $6,267,000 after acquiring an additional 4,876 shares in the last quarter. 90.12% of the stock is owned by institutional investors.

DaVita Trading Down 3.1 %

DaVita stock traded down $4.75 during midday trading on Tuesday, hitting $146.13. 402,936 shares of the stock were exchanged, compared to its average volume of 823,836. The stock's 50-day simple moving average is $151.61 and its 200 day simple moving average is $156.51. DaVita Inc. has a fifty-two week low of $125.64 and a fifty-two week high of $179.60. The company has a current ratio of 1.26, a quick ratio of 1.21 and a debt-to-equity ratio of 23.18. The stock has a market capitalization of $11.69 billion, a price-to-earnings ratio of 13.61, a PEG ratio of 1.07 and a beta of 1.04.

DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a net margin of 7.31% and a return on equity of 115.48%. On average, equities analysts anticipate that DaVita Inc. will post 10.76 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently commented on DVA. Sanford C. Bernstein set a $184.00 target price on shares of DaVita in a research note on Friday, February 21st. Barclays boosted their price objective on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a report on Tuesday, February 18th. Cowen restated a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, StockNews.com upgraded DaVita from a "hold" rating to a "buy" rating in a research note on Thursday, April 10th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and an average price target of $166.33.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.